Showing 7161-7170 of 9829 results for "".
- On Match Day, AMA Calls for Additional Residency Positions to Address Physician Shortagehttps://practicaldermatology.com/news/20130319-on_match_day_ama_calls_for_additional_residency_positions_to_address_physician_shortage/2459585/A statement released by Jeremy A. Lazarus, M.D., President of the American Medical Association, is seeking to raise awareness about the physician shortage. "Today, on Match Day, thousands of medical students will learn where they will complete their graduate medical education (GME), known as reside
- SkinMedica Unveils Hydroquinone-Free Skin Brightening Complexhttps://practicaldermatology.com/news/20130314-skinmedica_unveils_hydroquinone-free_skin_brightening_complex/2459588/SkinMedica introduced its new skin brightening product, SkinMedica Lytera™ Skin Brightening Complex, a hydroquinone-free product that reduces the appearance of skin discoloration and dark spots. Featuring a proprietary blend of ingredients, SkinMedica Lytera™ Skin Brightening Complex works to bright
- AMBI Skincare Announces Annual Skin of Color Society Research Awardhttps://practicaldermatology.com/news/20130312-ambi_skincare_announces_annual_skin_of_color_society_research_award/2459592/The annual AMBI Skin of Color Society Research Award was recently presented to Jenna O'Neill, MD, for her contribution to dermatological research in skin of color, specifically in characterizing the genetic basis of central centrifugal cicatricial alopecia. The Award is sponsored by a $15,000 grant
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Valeant Launches Acne Scholarship Programhttps://practicaldermatology.com/news/20130311-valeant_launches_acne_scholarship_program/2459598/Valeant Dermatology recently launched a scholarship program entitled, Acanya® I Can Succeed, an initiative that will provide college scholarship money to students who have had acne and have actively tried to address it. The Acanya I Can Succeed Scholarship program will award a total of up to $48,000
- Novan Therapeutics Presents Data for Potential Topical Agent that Reduces Sebum in Acne Patientshttps://practicaldermatology.com/news/20130228-novan_therapeutics_presents_data_for_potential_topical_agent_that_reduces_sebum_in_acne_patients/2459602/Recent in vitro and animal testing data from Novan Therapeutics indicate that the company's drug candidate, SB204, could lead to a topical treatment for acne that reduces oil production in the skin. Dr. Diane Thiboutot, Professor of Dermatology at Penn State Hershey College of Medicine, notes that,
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Medical Entrepreneur Symposium: Registration Open, Sponsors Invitedhttps://practicaldermatology.com/news/20130226-medical_entrepreneur_symposium_registration_open_sponsors_invited/2459606/The 2nd Annual The Medical Entrepreneur Symposium for physicians, office managers and physician entrepreneurs, to be held in Delray Beach, FL April 19-21, is expected to attract over 150 healthcare (and healthcare related) professionals an